A122 COMBINATION BIOLOGIC THERAPY IN INFLAMMATORY BOWEL DISEASE: THE CALGARY EXPERIENCE

BACKGROUND: Biologic therapy has revolutionized inflammatory bowel disease (IBD) care. More recently, newer biologics have been approved. Despite multiple options, clinical remission rates at one year are approximately 40% for any single biologic agent. In addition, questions surround the efficacy o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Can Assoc Gastroenterol
Egile Nagusiak: Panaccione, N, Novak, K L, Seow, C, Devlin, S, Lu, C, Heatherington, J, Kaplan, G G, Panaccione, R
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
Posters Of Distinction
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512451/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.121
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak